Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed Controls.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
17 08 2020
Historique:
received: 20 11 2019
accepted: 06 04 2020
pubmed: 9 4 2020
medline: 9 3 2021
entrez: 9 4 2020
Statut: ppublish

Résumé

In human blood, mucosal-associated invariant T (MAIT) cells are abundant T cells that recognize antigens presented on non-polymorphic major histocompatibility complex-related 1 (MR1) molecules. The MAIT cells are activated by mycobacteria, and prior human studies indicate that blood frequencies of MAIT cells, defined by cell surface markers, decline during tuberculosis (TB) disease, consistent with redistribution to the lungs. We tested whether frequencies of blood MAIT cells were altered in patients with TB disease relative to healthy Mycobacterium tuberculosis-exposed controls from Peru and South Africa. We quantified their frequencies using MR1 tetramers loaded with 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil. Unlike findings from prior studies, frequencies of blood MAIT cells were similar among patients with TB disease and latent and uninfected controls. In both cohorts, frequencies of MAIT cells defined by MR1-tetramer staining and coexpression of CD161 and the T-cell receptor alpha variable gene TRAV1-2 were strongly correlated. Disease severity captured by body mass index or TB disease transcriptional signatures did not correlate with MAIT cell frequencies in patients with TB. Major histocompatibility complex (MHC)-related 1-restrictied MAIT cells are detected at similar levels with tetramers or surface markers. Unlike MHC-restricted T cells, blood frequencies of MAIT cells are poor correlates of TB disease but may play a role in pathophysiology.

Sections du résumé

BACKGROUND
In human blood, mucosal-associated invariant T (MAIT) cells are abundant T cells that recognize antigens presented on non-polymorphic major histocompatibility complex-related 1 (MR1) molecules. The MAIT cells are activated by mycobacteria, and prior human studies indicate that blood frequencies of MAIT cells, defined by cell surface markers, decline during tuberculosis (TB) disease, consistent with redistribution to the lungs.
METHODS
We tested whether frequencies of blood MAIT cells were altered in patients with TB disease relative to healthy Mycobacterium tuberculosis-exposed controls from Peru and South Africa. We quantified their frequencies using MR1 tetramers loaded with 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil.
RESULTS
Unlike findings from prior studies, frequencies of blood MAIT cells were similar among patients with TB disease and latent and uninfected controls. In both cohorts, frequencies of MAIT cells defined by MR1-tetramer staining and coexpression of CD161 and the T-cell receptor alpha variable gene TRAV1-2 were strongly correlated. Disease severity captured by body mass index or TB disease transcriptional signatures did not correlate with MAIT cell frequencies in patients with TB.
CONCLUSIONS
Major histocompatibility complex (MHC)-related 1-restrictied MAIT cells are detected at similar levels with tetramers or surface markers. Unlike MHC-restricted T cells, blood frequencies of MAIT cells are poor correlates of TB disease but may play a role in pathophysiology.

Identifiants

pubmed: 32267943
pii: 5817894
doi: 10.1093/infdis/jiaa173
pmc: PMC7430171
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

995-1007

Subventions

Organisme : FIC NIH HHS
ID : D43 TW010559
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI049313
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI111224
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Infect Immun. 2018 Nov 20;86(12):
pubmed: 30201702
Immunol Cell Biol. 2018 Jul;96(6):607-617
pubmed: 29451704
Immunity. 2016 Jan 19;44(1):32-45
pubmed: 26795251
Immunol Cell Biol. 2018 May;96(5):507-525
pubmed: 29437263
Tuberculosis (Edinb). 2017 Dec;107:48-58
pubmed: 29050771
Sci Immunol. 2018 Jul 13;3(25):
pubmed: 30006464
Front Immunol. 2019 Feb 14;10:206
pubmed: 30853958
Nat Commun. 2016 Aug 16;7:12506
pubmed: 27527800
Clin Microbiol Rev. 2014 Jan;27(1):3-20
pubmed: 24396134
Annu Rev Public Health. 2013;34:271-86
pubmed: 23244049
Lancet. 2016 Jun 4;387(10035):2312-2322
pubmed: 27017310
Nat Commun. 2019 Feb 8;10(1):687
pubmed: 30737409
PLoS One. 2011 Mar 29;6(3):e17984
pubmed: 21479236
Front Microbiol. 2019 Jun 26;10:1441
pubmed: 31297103
Tuberculosis (Edinb). 2019 May;116S:S11-S18
pubmed: 31072689
J Clin Invest. 2020 Jan 2;130(1):214-230
pubmed: 31763997
Nat Commun. 2019 May 21;10(1):2243
pubmed: 31113973
J Immunol. 2019 Dec 1;203(11):2917-2927
pubmed: 31611259
JAMA Netw Open. 2018 Oct 5;1(6):e183779
pubmed: 30646264
Nat Immunol. 2010 Aug;11(8):701-8
pubmed: 20581831
Infect Immun. 2012 Sep;80(9):3256-67
pubmed: 22778103
J Exp Med. 1993 Jul 1;178(1):1-16
pubmed: 8391057
Scand J Immunol. 2014 Oct;80(4):271-5
pubmed: 24846411
J Immunol. 2015 Sep 1;195(5):1927-32
pubmed: 26297792
J Exp Med. 2013 Oct 21;210(11):2305-20
pubmed: 24101382
Nature. 2010 Aug 19;466(7309):973-7
pubmed: 20725040
Tuberculosis (Edinb). 2018 Jan;108:124-126
pubmed: 29523312
Immunology. 2015 Jul;145(3):443-53
pubmed: 25752900
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282828
Am J Respir Crit Care Med. 2018 May 1;197(9):1198-1208
pubmed: 29624071
Front Immunol. 2020 Feb 14;11:199
pubmed: 32117314
J Exp Med. 1999 Jun 21;189(12):1907-21
pubmed: 10377186
Epidemics. 2016 Mar;14:54-61
pubmed: 26972514
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
Sci Rep. 2020 May 25;10(1):8629
pubmed: 32451443
EMBO Mol Med. 2015 Dec 18;8(2):86-95
pubmed: 26682570
J Exp Med. 2014 Jul 28;211(8):1585-600
pubmed: 25049336
Nature. 2012 Nov 29;491(7426):717-23
pubmed: 23051753
Commun Biol. 2019 Jun 5;2:203
pubmed: 31231693
J Infect. 2016 Mar;72(3):338-52
pubmed: 26724769
Blood. 2012 Jan 12;119(2):422-33
pubmed: 22086415
Immunol Cell Biol. 2018 Jul;96(6):573-587
pubmed: 29656544
PLoS Biol. 2010 Jun 29;8(6):e1000407
pubmed: 20613858
Lancet Respir Med. 2016 Mar;4(3):213-24
pubmed: 26907218
Nat Immunol. 2013 Jul;14(7):706-13
pubmed: 23727893
J Immunol. 2018 Nov 15;201(10):2862-2871
pubmed: 30397170
Tuberculosis (Edinb). 2015 May;95(3):267-74
pubmed: 25837440
Front Immunol. 2019 Feb 19;10:260
pubmed: 30838000
Nature. 2014 May 15;509(7500):361-5
pubmed: 24695216
Tubercle. 1948 Nov;29(11):245-51
pubmed: 18101320

Auteurs

Sara Suliman (S)

Division of Rheumatology, Immunity and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Anele Gela (A)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Simon C Mendelsohn (SC)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Sarah K Iwany (SK)

Division of Rheumatology, Immunity and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Kattya Lopez Tamara (KL)

Division of Rheumatology, Immunity and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Socios En Salud Sucursal Peru, Lima, Peru.

Simbarashe Mabwe (S)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Nicole Bilek (N)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Fatoumatta Darboe (F)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Michelle Fisher (M)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Alexandra J Corbett (AJ)

Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Lars Kjer-Nielsen (L)

Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Sidonia B G Eckle (SBG)

Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Chuan-Chin Huang (CC)

Department of Global Health and Social Medicine, and Division of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Zibiao Zhang (Z)

Department of Global Health and Social Medicine, and Division of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

David M Lewinsohn (DM)

Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland VA Medical Center, Portland, Oregon, USA.

James McCluskey (J)

Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Jamie Rossjohn (J)

Infection and Immunity Program and The Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.
Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom.

Mark Hatherill (M)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Segundo R León (SR)

Socios En Salud Sucursal Peru, Lima, Peru.

Roger I Calderon (RI)

Socios En Salud Sucursal Peru, Lima, Peru.

Leonid Lecca (L)

Socios En Salud Sucursal Peru, Lima, Peru.
Department of Global Health and Social Medicine, and Division of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Megan Murray (M)

Department of Global Health and Social Medicine, and Division of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Thomas J Scriba (TJ)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Ildiko Van Rhijn (I)

Division of Rheumatology, Immunity and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

D Branch Moody (DB)

Division of Rheumatology, Immunity and Inflammation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH